Ipsen receives CRL for potential bone treatment 05-Jan-2023 By Ben Hargreaves The drug candidate palovarotene is knocked back by the FDA, as the agency requests additional information on clinical trial data.
FT Pharmaceutical & Biotechnology Conference Ipsen on the ‘biotech mindset’ and how to ‘focus on the why’ 20-Nov-2019 By Vassia Barba Speaking at the FT Pharmaceutical & Biotechnology conference earlier this week, Ipsen’s CCO said that pharma manufacturers need to focus more on the ‘why’.